Lam Research jumps 3.7% amid semiconductor-equipment rebound and fresh S&P 100 addition

Lam Research (LRCX) is up 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks tied to improving sentiment in semiconductor-capex and equipment names after a recent bout of volatility, with investors rotating back into higher-beta AI infrastructure plays. Separate from the day’s tape, LRCX has also had multiple supportive fundamentals in the background—strong quarterly results and an upcoming index inclusion that can boost incremental passive demand.

Details:

S&P Dow Jones Indices announced on March 6, 2026 that Lam Research will be added to the S&P 100, effective prior to the market open on March 23, 2026.

Lam’s Jan. 28, 2026 earnings release showed December-quarter revenue of $5.34 billion and non-GAAP EPS of $1.27, alongside guidance for the quarter ending March 29, 2026 of revenue at $5.70 billion (± $300 million).

A recent Morgan Stanley note highlighted unusually extended demand visibility for leading wafer-fab equipment vendors and pointed to capacity constraints as a limiting factor for 2026 industry output.

This could also be amplified by broad “risk-on” flows into large-cap semiconductors, where LRCX often trades as a liquid proxy for fab spending expectations.

Sources:

Lam Research Investor Relations, S&P Dow Jones Indices, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LRCX Insider Trading Activity

$LRCX insiders have traded $LRCX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $LRCX stock by insiders over the last 6 months:

TIMOTHY ARCHER (President and CEO) has made 0 purchases and 2 sales selling 163,300 shares for an estimated $26,758,338.
DOUGLAS R BETTINGER (Chief Financial Officer & EVP) has made 0 purchases and 3 sales selling 130,466 shares for an estimated $26,534,860.
ERIC BRANDT has made 0 purchases and 2 sales selling 35,000 shares for an estimated $7,896,150.
VAHID VAHEDI (Senior Vice President) sold 52,190 shares for an estimated $7,249,191
AVA HARTER (Chief Legal Officer) has made 0 purchases and 4 sales selling 14,510 shares for an estimated $2,682,764.
BETHANY MAYER has made 0 purchases and 2 sales selling 1,328 shares for an estimated $212,452.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$LRCX Hedge Fund Activity

We have seen 1,054 institutional investors add shares of $LRCX stock to their portfolio, and 1,077 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 38,239,309 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $6,545,804,914
PRICE T ROWE ASSOCIATES INC /MD/ added 10,666,540 shares (+352.2%) to their portfolio in Q4 2025, for an estimated $1,825,898,317
BLACKROCK, INC. added 10,000,727 shares (+8.0%) to their portfolio in Q4 2025, for an estimated $1,711,924,447
JPMORGAN CHASE & CO removed 6,436,253 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $1,101,757,788
NORDEA INVESTMENT MANAGEMENT AB removed 3,909,309 shares (-34.6%) from their portfolio in Q4 2025, for an estimated $669,195,514
FRANKLIN RESOURCES INC added 3,671,073 shares (+57.0%) to their portfolio in Q4 2025, for an estimated $628,414,276
CORIENT PRIVATE WEALTH LLC added 3,649,553 shares (+235.5%) to their portfolio in Q4 2025, for an estimated $624,730,482

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LRCX Congressional Stock Trading

Members of Congress have traded $LRCX stock 11 times in the past 6 months. Of those trades, 2 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $LRCX stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR has traded it 7 times. They made 0 purchases and 7 sales worth up to $175,000 on 02/26, 01/16, 01/08, 09/22.
REPRESENTATIVE CLEO FIELDS purchased up to $50,000 on 02/03.
SENATOR JOHN BOOZMAN sold up to $15,000 on 01/08.
SENATOR MARKWAYNE MULLIN purchased up to $100,000 on 12/29.
REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$LRCX Analyst Ratings

Wall Street analysts have issued reports on $LRCX in the last several months. We have seen 14 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Goldman Sachs issued a "Buy" rating on 01/29/2026
Needham issued a "Buy" rating on 01/29/2026
Wells Fargo issued a "Overweight" rating on 01/15/2026
RBC Capital issued a "Outperform" rating on 01/15/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Mizuho issued a "Outperform" rating on 01/09/2026
B. Riley Securities issued a "Buy" rating on 12/18/2025

To track analyst ratings and price targets for $LRCX, check out Quiver Quantitative's $LRCX forecast page.

$LRCX Price Targets

Multiple analysts have issued price targets for $LRCX recently. We have seen 22 analysts offer price targets for $LRCX in the last 6 months, with a median target of $261.0.

Here are some recent targets:

Tom O'Malley from Barclays set a target price of $255.0 on 03/10/2026
Joseph Moore from Morgan Stanley set a target price of $254.0 on 02/25/2026
Charles Shi from Needham set a target price of $300.0 on 01/29/2026
Toshiya Hari from Goldman Sachs set a target price of $262.0 on 01/29/2026
Joseph Quatrochi from Wells Fargo set a target price of $290.0 on 01/29/2026
Brian Chin from Stifel set a target price of $280.0 on 01/29/2026
Srini Pajjuri from RBC Capital set a target price of $290.0 on 01/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.